Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.

ABSTRACT:

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD.

Aims

To assess the effects of this new nomenclature on the prevalence and distribution of different SLD categories in people with HIV (PWH) and identified factors associated with MASLD and clinically significant fibrosis (CSF).

Methods

PWH were prospectively enrolled from 9 US centres and underwent clinical evaluation and vibration-controlled transient elastography for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). SLD was defined as CAP ≥ 263 dB/m, CSF as LSM of ≥8 kPa, and advanced fibrosis (AF) as LSM ≥ 12 kPa. The prevalence of SLD, MASLD, metabolic dysfunction and alcohol-associated liver disease (M

SUBMITTER: Gawrieh S 

PROVIDER: S-EPMC10922859 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature